Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Treatment of hepatocellular carcinoma with liver transplantation – experience at Clinical Hospital Merkur (CROSBI ID 567492)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Mikulić, Danko ; Jadrijević, Stipislav ; Škopljanac, Andrija ; Kocman, Ivica ; Suknaić, Slaven ; Mrzljak, Anna ; Kocman, Branislav Treatment of hepatocellular carcinoma with liver transplantation – experience at Clinical Hospital Merkur // European Surgery. 2010. str. 11-11

Podaci o odgovornosti

Mikulić, Danko ; Jadrijević, Stipislav ; Škopljanac, Andrija ; Kocman, Ivica ; Suknaić, Slaven ; Mrzljak, Anna ; Kocman, Branislav

engleski

Treatment of hepatocellular carcinoma with liver transplantation – experience at Clinical Hospital Merkur

Orthotopic liver transplantation (OLT) is the most efficient option for the treatment of hepatocellular carcinoma(HCC) in terms of survival and recurrence rate provided that restrictive selection criteria are applied. However, tumor recurrence occurs in 3.5–30% of recipients and it has a negative impact on prognosis. In this retrospective study we analyzed survival and tumor recurrence rate in a cohort of patients with HCC treated with OLT in a single center. Between 2005 and 2009 30 patients with HCC were transplanted. Mean age was 58þ5.28 years. Twenty-two patients were male and 8 were female. Etiology was viral in 12 patients (30%), alcoholic in 14 (46.6%) and miscellaneous in 4 patients (13.3%). After a median follow-up of 30.8 months, 25 recipients(83.3%) were alive. Eight patients (26.6%) had disease recurrence. Twenty-one patients (70%) were transplanted within and 9 patients (30%) were outside Milan criteria. A higher recurrence rate was noted in patients surpassing the Milan criteria. OLT is an effective mode of treatment for patients with HCC providing low recurrence rates and survival comparable to liver transplantation for benign disease if restrictive selection criteria are applied

hepatocellular carcinoma; liver transplantation

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

11-11.

2010.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

European Surgery

Springer

1682-8631

Podaci o skupu

Nepoznat skup

predavanje

29.02.1904-29.02.2096

Povezanost rada

Kliničke medicinske znanosti